Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1621 4100
This examiner grants 54% of resolved cases
Josmalen Milagros Ramos Lewis examines in Tech Center 4100 and Art Unit 1621. With 69 resolved cases, the allowance rate is 53.6 percent. This indicates the level of difficulty for applicants. The median days to allowance is 1081, which is the duration for successful prosecution. These 69 resolved cases establish the current performance metrics for this examiner.
The interview lift is 23.9 percent, suggesting that interviews are effective at increasing the 53.6 percent baseline allowance rate. For the 69 cases in the data, the lift indicates that verbal discussion is a key tactic for resolving issues. Practitioners should use the 1081-day median pendency as a guide for timing while seeking interviews to improve their chances. The 23.9 percent lift provides a clear path to improve the 53.6 percent allowance rate in Art Unit 1621.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | Final Rejection | Bristol-Myers Squibb Company |
| 18594178 | Chlorthalidone Compositions And Methods | Non-Final OA | Nivagen Pharmaceuticals, Inc. |
| 17422074 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS THEREOF | Final Rejection | University of Washington |
| 17511635 | MEK INHIBITORS FOR CORNEAL SCARRING AND NEOVASCULARIZATION | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 19067074 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | Non-Final OA | GSKB Pharmaceuticals, LLC |
| 18633291 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | Non-Final OA | GSKB Pharmaceuticals, LLC |
| 17396292 | GREEN POLYETHYLENE WAX FOR HOT MELT ADHESIVES, COATINGS, AND COSMETICS | Non-Final OA | Braskem S.A. |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | Non-Final OA | Woolsey Pharmaceuticals, Inc. |
| 18736787 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | Non-Final OA | Epitech Group S.P.A. |
| 18566777 | PHARMACEUTICAL SALTS OF A CHK-1 INHIBITOR | Non-Final OA | PHARMAENGINE, INC. |
| 18462571 | PROCESSES AND APPARATUS FOR EXTRACTION OF SUBSTANCES AND ENRICHED EXTRACTS FROM PLANT MATERIAL | Non-Final OA | BIOMASS OIL SEPARATION SOLUTIONS, LLC |
| 18259964 | PHARMACEUTICAL COMPOSITION FOR INHALATION | Final Rejection | SHANGHAI HUILUN JIANGSU PHARMACEUTICAL CO., LTD. |
| 18027036 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | HISUN ACCURAY THERAPEUTICS CO., LTD. |
| 18145986 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | Non-Final OA | VIB vzw |
| 17283627 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | Final Rejection | CRYSTALGENOMICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy